According to TipRanks, Bedford is a 5-star analyst with an average return of 8.6% and a 59.56% success rate. Bedford covers the Healthcare sector, focusing on stocks such as AxoGen, Dexcom, and Insulet.
Abbott Laboratories has an analyst consensus of Strong Buy, with a price target consensus of $119.31, which is a 18.50% upside from current levels. In a report released on July 17, Citi also maintained a Buy rating on the stock with a $112.00 price target.
Based on Abbott Laboratories’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $11.16 billion and a net profit of $1.08 billion. In comparison, last year the company earned a revenue of $10.36 billion and had a net profit of $1.33 billion
Based on the recent corporate insider activity of 45 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ABT in relation to earlier this year. Last month, John Stratton, a Director at ABT bought 2,000.00 shares for a total of $173,640.00.
